Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician's perspective
Por:
Guglielmetti, L, Chiesi, S, Eimer, J, Dominguez, J, Masini, T, Varaine, F, Veziris, N, Ader, F and Robert, J
Publicada:
1 jun 2020
Ahead of Print:
23 jul 2020
Resumen:
Drug-resistant tuberculosis (TB) represents a substantial threat to the global efforts to control this disease. After decades of stagnation, the treatment of drug-resistant TB is undergoing major changes: two drugs with a new mechanism of action, bedaquiline and delamanid, have been approved by stringent regulatory authorities and are recommended by the WHO. This narrative review summarizes the evidence, originating from both observational studies and clinical trials, which is available to support the use of these drugs, with a focus on special populations. Areas of uncertainty, including the use of the two drugs together or for prolonged duration, are discussed. Ongoing clinical trials are aiming to optimize the use of bedaquiline and delamanid to shorten the treatment of drug-resistant TB.
Filiaciones:
Guglielmetti, L:
Sorbonne Univ, Hop Pitie Salpetriere, Ctr Natl Reference Mycobacteries & Resistance Myc, APHP,Grp Hosp Univ, F-75013 Paris, France
Sorbonne Univ, INSERM, Ctr Immunol & Malad Infect, U1135, Equipe 2, F-75013 Paris, France
Med Sans Frontieres, Paris, France
Chiesi, S:
GB Rossi Hosp, Dept Infect Dis, Verona, Italy
Univ Verona, Verona, Italy
Eimer, J:
Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden
:
Univ Autonoma Barcelona, Res Inst Germans Trias & Pujol, CIBER Resp Dis, Badalona, Spain
Varaine, F:
Med Sans Frontieres, Paris, France
Veziris, N:
Sorbonne Univ, INSERM, Ctr Immunol & Malad Infect, U1135, Equipe 2, F-75013 Paris, France
Hop Univ Est Parisien, APHP, Ctr Natl Reference Mycobacteries & Resistance Myc, Dept Bacteriol, F-75012 Paris, France
Ader, F:
Hosp Civils Lyon, Dept Malad Infect & Trop, F-69004 Lyon, France
Univ Lyon, Univ Claude Bernard Lyon 1, Ctr Int Rech Infectiol CIRI, INSERM 1111,CNRS,Ecole Normale Super Lyon,UMR5308, F-69007 Lyon, France
Robert, J:
Sorbonne Univ, Hop Pitie Salpetriere, Ctr Natl Reference Mycobacteries & Resistance Myc, APHP,Grp Hosp Univ, F-75013 Paris, France
Sorbonne Univ, INSERM, Ctr Immunol & Malad Infect, U1135, Equipe 2, F-75013 Paris, France
|